Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effect...

Full description

Bibliographic Details
Main Authors: Helmut Butzkueven, Paul S. Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz, Ying Zhang, Yvonne Geissbühler, Diego Silva, Davorka Tomic, Harald Kropshofer, Maria Trojano
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Brain Sciences
Subjects:
fingolimod
natalizumab
switching
transition
observational study
Online Access:https://www.mdpi.com/2076-3425/12/2/215

Internet

https://www.mdpi.com/2076-3425/12/2/215

Similar Items